Target intelligence / Profile preview

POU class 2 homeobox associating factor 2 (POU2AF2)

Target
POU2AF2
Molecular classification
Transcription cofactor (transcriptional co-activator), Other (does not possess classical DNA-binding or chromatin-binding domains)
01

Overview

POU class 2 homeobox associating factor 2 (POU2AF2, also known as C11orf53 or OCA-T1) is a transcriptional co-activator that plays a pivotal role in maintaining enhancer activity and chromatin accessibility, primarily through its partnership with the master transcription factor POU2F3[1][3][4]. POU2AF2 is essential for the maintenance and differentiation of tuft cells in various epithelial tissues, influencing gene expression by co-activating distal enhancer elements and interacting with chromatin remodeling complexes such as SWI/SNF[1][2][3]. Genetic depletion of POU2AF2 leads to altered transcriptional landscapes, chromatin structure changes, and can impair cell viability—particularly in tuft-cell-like small cell lung cancer, making it a candidate therapeutic target within this cancer subtype[1][3]. POU2AF2 does not function as a classical DNA-binding factor: it lacks direct chromatin recognition domains, instead it is recruited to chromatin by POU2F3 to facilitate open chromatin and regulate lineage-specific gene expression. Additionally, POU2AF2 is identified as a critical regulator for tuft cell-mediated immune responses in tissues such as the gut, highlighting its broader role in epithelial biology and immunity[4]. No direct drug interactions or approved therapeutics currently target POU2AF2, though its pathway is considered a potential intervention strategy for certain cancers[1].

Other names
OCA-T1C11orf53Protein OCA-T1Oct coactivator from tuft cells 1OCAT1MGC50104uncharacterized protein C11orf53
02

Biological functions

Regulator of enhancer activityMediator of chromatin accessibilityEssential for tuft cell differentiation and identityInfluences SWI/SNF chromatin remodelingMaintains open chromatin states for transcription factor targets
03

Disease associations

Cancer (notably small cell lung cancer, SCLC-P subtype)Other (epithelial cell differentiation, potentially type 2 immunity regulation)
04

Safety considerations

Potential for off-target effects if used as therapeutic target due to role in cell viability and chromatin regulationAltered immune responses or epithelial cell differentiation if targeted systemically
05

Biomarkers

Tuft cell differentiation (e.g., SCLC-P subtype marker)

Beyond the preview

Go deeper on POU class 2 homeobox associating factor 2 (POU2AF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on POU class 2 homeobox associating factor 2 (POU2AF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call